Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Getting a Handle on Lymphopenia With Tecfidera
Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS.
Multiple sclerosis: A lifestyle disease?
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
The impact of multiple sclerosis relapse treatment on migration of effector T cells - Preliminary study.
Episode 6 with Dr. Jeffrey Dunn on biomarkers and personalized medicine
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
EU regulator warns on possible MS drugs side effects
Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
Emerging oral agents for multiple sclerosis.
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Multiple sclerosis in 2014: Progress in MS-classification, mechanisms and treatment.

Pages